Broad-spectrum receptor tyrosine kinase inhibitors overcome <i>de novo</i> and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer.

Graves-Deal, Ramona; Bogatcheva, Galina; Rehman, Saba; Lu, Yuanyuan; Higginbotham, James N; Singh, Bhuminder

Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer.

Graves-Deal, Ramona; Bogatcheva, Galina; Rehman, Saba; Lu, Yuanyuan; Higginbotham, James N; Singh, Bhuminder.

Afiliação

Graves-Deal R; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Bogatcheva G; Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rehman S; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Lu Y; Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Higginbotham JN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Singh B; Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Oncotarget ; 10(13): 1320-1333, 2019 Feb 12.

Article em En | MEDLINE | ID: mdl-30863492

Palavras-chave

EGFR; MET; RTK inhibition; cetuximab resistance; colorectal cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google